Answers are grounded in this paper and cite their sources.
Clinical review uncovers diagnostic and treatment pathways for PPI-refractory reflux symptoms, highlighting the need to distinguish functional disorders from persistent non-acid reflux.
Approximately a third of patients with suspected gastro-oesophageal reflux disease are resistant or partial responders to proton pump inhibitors (PPIs). Many of these patients do not have gastro-oesophageal reflux disease, but suffer from functional heartburn or dyspepsia. The potential mechanisms underlying failure of PPI treatment in patients with reflux-related symptoms include persistence of isolated or mixed acid, weakly acidic, bile or gas reflux, impaired oesophageal mucosal integrity, chemical or mechanical hypersensitivity to refluxates and psychological comorbidity. After thorough clinical evaluation and failure of empirical changes in PPI dose regime, diagnostic investigations include endoscopy and reflux monitoring with pH or pH-impedance monitoring. If symptoms are clearly related to persistent reflux, baclofen, antireflux surgery or pain modulators can be considered. If not, pain modulators are the only currently available therapy.
No takes yet. Share an insight, caveat, or question.
Sifrim et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: